Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco ...
Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports ...
Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K.
Viewers follow a twisted fairytale, watching as Rigel breaks free from a toxic upbringing by overcoming emotional torture and ...
B. Riley lowered the firm’s price target on Rigel Pharmaceuticals (RIGL) to $20 from $27 and keeps a Neutral rating on the shares after the company delivered updated data for R289 in lower-risk ...
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report) and keeping the price target at ...
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback